When evaluating the potential reimbursement for a new health technology, payers will assess the balance between health benefits (measured in QALY gains) and associated costs.
In this video fragment from our online self-study programme Basics of Health Economics, Prof. Dr. Lieven Annemans explains the 2 key dimensions that determine the cost-effectiveness of this new health technology (drug, medtech device, prevention programme…).
Learn more about this highly recommended online self-study programme:
Online Self-Study Programme: Basics of Health Economics
With Prof. Dr. Lieven Annemans
